KR102602502B1 - 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 - Google Patents

신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 Download PDF

Info

Publication number
KR102602502B1
KR102602502B1 KR1020227025504A KR20227025504A KR102602502B1 KR 102602502 B1 KR102602502 B1 KR 102602502B1 KR 1020227025504 A KR1020227025504 A KR 1020227025504A KR 20227025504 A KR20227025504 A KR 20227025504A KR 102602502 B1 KR102602502 B1 KR 102602502B1
Authority
KR
South Korea
Prior art keywords
sema4d
antibody
ser
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227025504A
Other languages
English (en)
Korean (ko)
Other versions
KR20220110853A (ko
Inventor
어니스트 에스 스미스
모리스 자우더러
윌리엄 제이 바우어스
알런 조나슨
Original Assignee
백시넥스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 백시넥스 인코포레이티드 filed Critical 백시넥스 인코포레이티드
Priority to KR1020237038769A priority Critical patent/KR20230159633A/ko
Publication of KR20220110853A publication Critical patent/KR20220110853A/ko
Application granted granted Critical
Publication of KR102602502B1 publication Critical patent/KR102602502B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227025504A 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 Active KR102602502B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237038769A KR20230159633A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361893814P 2013-10-21 2013-10-21
US61/893,814 2013-10-21
US201461979384P 2014-04-14 2014-04-14
US61/979,384 2014-04-14
US201462012805P 2014-06-16 2014-06-16
US62/012,805 2014-06-16
KR1020217030075A KR20210118246A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
PCT/US2014/061592 WO2015061330A1 (en) 2013-10-21 2014-10-21 Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030075A Division KR20210118246A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038769A Division KR20230159633A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도

Publications (2)

Publication Number Publication Date
KR20220110853A KR20220110853A (ko) 2022-08-09
KR102602502B1 true KR102602502B1 (ko) 2023-11-14

Family

ID=52826380

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020167013445A Active KR102308493B1 (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
KR1020217030075A Ceased KR20210118246A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
KR1020227025504A Active KR102602502B1 (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
KR1020237038769A Ceased KR20230159633A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020167013445A Active KR102308493B1 (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
KR1020217030075A Ceased KR20210118246A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237038769A Ceased KR20230159633A (ko) 2013-10-21 2014-10-21 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도

Country Status (19)

Country Link
US (4) US9598495B2 (enExample)
EP (2) EP3639853A1 (enExample)
JP (2) JP6461944B2 (enExample)
KR (4) KR102308493B1 (enExample)
CN (2) CN106029093B (enExample)
AU (3) AU2014340210B2 (enExample)
BR (1) BR112016009047B1 (enExample)
CA (2) CA3193983A1 (enExample)
DK (1) DK3060252T3 (enExample)
EA (1) EA033072B1 (enExample)
ES (1) ES2773961T3 (enExample)
IL (3) IL295045B2 (enExample)
MX (2) MX374708B (enExample)
NZ (1) NZ630892A (enExample)
PL (1) PL3060252T3 (enExample)
PT (1) PT3060252T (enExample)
SG (2) SG11201603167YA (enExample)
WO (1) WO2015061330A1 (enExample)
ZA (1) ZA201602686B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
KR101999872B1 (ko) 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US10626163B2 (en) * 2013-01-25 2020-04-21 Brandeis University Methods of modulating GABAergic inhibitory synapse formation and function
WO2014209802A1 (en) 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
PT3445397T (pt) 2016-04-22 2023-01-13 Vaccinex Inc Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
JP7084689B2 (ja) * 2016-12-08 2022-06-15 公益財団法人東京都医学総合研究所 脳組織の異常を伴う非ヒト動物の作製方法およびその利用
BR112019017367A2 (pt) * 2017-02-22 2020-04-14 Vaccinex Inc detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias
EP3600419B1 (en) 2017-03-20 2023-08-09 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
MX2019013110A (es) 2017-05-05 2019-12-16 Vaccinex Inc Anticuerpo anti-semaforina 4d humano.
CN109410218B (zh) * 2018-10-08 2020-08-11 百度在线网络技术（北京）有限公司 用于生成车辆损伤信息的方法和装置
EP3693380A1 (en) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
CN117597360A (zh) 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用
JPWO2022137964A1 (enExample) * 2020-12-23 2022-06-30
IL311639A (en) * 2021-09-27 2024-05-01 Vaccinex Inc Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseases
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
AU2024243083A1 (en) * 2023-04-03 2025-11-20 Sialbio Co., Ltd. Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient
CN117924494B (zh) * 2024-01-23 2025-02-25 首都医科大学附属北京积水潭医院 特异性结合sema4d的抗原结合蛋白及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055922A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
EP0973916A1 (en) 1997-04-11 2000-01-26 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
DE69839970D1 (de) 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
WO2003101485A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
RS20050885A (sr) 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
US20060147449A1 (en) * 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
AU2006235271B2 (en) 2005-04-07 2011-05-19 Novartis Vaccines And Diagnostics Inc. SEMA4D in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
AR070134A1 (es) 2008-01-10 2010-03-17 Genentech Inc Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso
JP6059013B2 (ja) * 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
US9539320B2 (en) 2009-05-15 2017-01-10 Irx Therapeutics, Inc. Vaccine immunotherapy
EP2579895A4 (en) 2010-06-14 2013-12-18 Vaccinex Inc ANTI-VEGF ANTIBODIES AND USES THEREOF
CN103945868B (zh) 2011-05-13 2016-10-26 国立大学法人东京医科齿科大学 骨生成促进剂
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2014209802A1 (en) 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
PT3445397T (pt) 2016-04-22 2023-01-13 Vaccinex Inc Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus
IL264343B2 (en) 2016-08-02 2024-05-01 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
BR112019017367A2 (pt) 2017-02-22 2020-04-14 Vaccinex Inc detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055922A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brain Research, 제1142권, 223-236면(2007.1.27.)*

Also Published As

Publication number Publication date
EP3060252B1 (en) 2019-12-11
CN116966293A (zh) 2023-10-31
US20150353641A1 (en) 2015-12-10
MX2020009260A (es) 2020-10-01
IL275720B (en) 2022-09-01
CA2927841A1 (en) 2015-04-30
EA033072B1 (ru) 2019-08-30
KR20160065981A (ko) 2016-06-09
JP6461944B2 (ja) 2019-01-30
AU2021202095B9 (en) 2023-11-09
US20170198053A1 (en) 2017-07-13
KR20220110853A (ko) 2022-08-09
US10385136B2 (en) 2019-08-20
MX374708B (es) 2025-03-06
AU2021202095B2 (en) 2023-11-02
IL245089A0 (en) 2016-06-30
US9598495B2 (en) 2017-03-21
CA3193983A1 (en) 2015-04-30
EP3060252A1 (en) 2016-08-31
EA201690813A1 (ru) 2016-08-31
US9249227B2 (en) 2016-02-02
EP3639853A1 (en) 2020-04-22
KR102308493B1 (ko) 2021-10-07
AU2021202095A1 (en) 2021-05-06
PT3060252T (pt) 2020-03-04
KR20210118246A (ko) 2021-09-29
MX2016005050A (es) 2016-08-17
IL295045A (en) 2022-09-01
IL245089B (en) 2020-10-29
EP3060252A4 (en) 2017-06-07
IL295045B2 (en) 2024-04-01
BR112016009047A2 (pt) 2017-09-19
AU2019257379A1 (en) 2019-11-14
KR20230159633A (ko) 2023-11-21
AU2014340210B2 (en) 2019-08-08
AU2014340210A1 (en) 2016-05-05
CN106029093A (zh) 2016-10-12
SG10201707786QA (en) 2017-10-30
US20190322757A1 (en) 2019-10-24
WO2015061330A1 (en) 2015-04-30
US20150110800A1 (en) 2015-04-23
CN106029093B (zh) 2023-03-28
SG11201603167YA (en) 2016-05-30
IL275720A (en) 2020-08-31
PL3060252T3 (pl) 2020-05-18
NZ630892A (en) 2016-03-31
JP2017502920A (ja) 2017-01-26
AU2019257379B2 (en) 2021-04-01
JP6875363B2 (ja) 2021-05-26
JP2019059786A (ja) 2019-04-18
BR112016009047B1 (pt) 2024-02-06
ES2773961T3 (es) 2020-07-15
CA2927841C (en) 2023-05-23
DK3060252T3 (da) 2020-03-16
IL295045B1 (en) 2023-12-01
ZA201602686B (en) 2020-11-25
US10800853B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
AU2021202095B2 (en) Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
RU2766341C2 (ru) Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях
EA044133B1 (ru) Способ лечения симптомов ранней стадии болезни альцгеймера у субъекта

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220721

Application number text: 1020217030075

Filing date: 20210916

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221212

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230322

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221212

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230322

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230213

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20230810

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230622

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230322

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230213

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231110

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231110

End annual number: 3

Start annual number: 1

PG1601 Publication of registration